Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Protalix ( (PLX) ) has issued an update.
On August 22, 2025, Protalix BioTherapeutics, Inc. amended its At The Market Offering Agreement with H.C. Wainwright & Co., LLC, allowing the company to offer and sell shares of its common stock through an equity offering program. This amendment aligns with the company’s new registration statement, potentially impacting its market operations and stakeholder interests.
The most recent analyst rating on (PLX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Protalix stock, see the PLX Stock Forecast page.
Spark’s Take on PLX Stock
According to Spark, TipRanks’ AI Analyst, PLX is a Neutral.
Protalix’s overall stock score reflects its improving financial performance and positive earnings outlook, driven by strong revenue growth and strategic partnerships. However, concerns about leverage, inconsistent revenue growth, and valuation metrics temper the score.
To see Spark’s full report on PLX stock, click here.
More about Protalix
Protalix BioTherapeutics, Inc. is a Delaware-based company operating in the biopharmaceutical industry. The company focuses on developing and commercializing recombinant therapeutic proteins through its proprietary plant cell-based protein expression system.
Average Trading Volume: 820,360
Technical Sentiment Signal: Sell
Current Market Cap: $122M
See more insights into PLX stock on TipRanks’ Stock Analysis page.